Simavita Limited

Simavita Limited

February 20, 2014 17:32 ET

Simavita Limited Commences Trading on the ASX

SYDNEY, AUSTRALIA--(Marketwired - Feb. 20, 2014) - Simavita Limited ("Simavita" or the "Company") (TSX VENTURE:SV)(ASX:SVA) announces that its CHESS Depositary Interests ("CDI") commenced trading on the Australian Securities Exchange ("ASX") Official List on Thursday, February 20, 2014 (Sydney time). Simavita's CDIs commenced trading on the ASX under the trading symbol "SVA". The trading symbol on the TSXV remains "SV".

In connection with Simavita's ASX listing, Simavita issued 990,159 CDIs at an issue price of A$0.41 per CDI for gross proceeds of A$405,965. As previously announced, the CDIs were issued pursuant to a prospectus filed in Australia with the Australian Securities and Investment Commission. One common share of Simavita was issued in the name of CHESS Depositary Nominees Pty Ltd as nominee for each CDI. CDIs are frequently used for trading foreign common shares on the ASX. CDIs are traded in a manner similar to common shares.

For further information, please check our website ( or contact the persons outlined below.

About Simavita

Simavita is a medical device company that has developed an innovative, world first solution for the management of urinary incontinence, with a focus on the elderly. The first product is the SIM™ platform technology which is an instrumented incontinence assessment application that provides evidence based incontinence management care plans to the residential aged care market.

About SIM

SIM™ is a wireless sensor technology that delivers evidence-based instrument incontinence data on individuals. SIM™ provides user friendly tools and software to assess the incontinence condition and to help plan better outcomes. SIM™ is used to detect, record and report incontinence events during a compulsory or recommended assessment period in residential aged care facilities to develop an evidence-based incontinence care plan.

Conducting assessments is mandatory in many countries and the incontinence assessment creates an influential element of care of each individual. For more information on Simavita or SIM™, please visit

The TSX Venture Exchange has in no way passed upon the merits of the transactions set out herein and has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange not its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this Release.

Contact Information